Idarubicin Accord

Idarubicin, the active ingredient in Idarubicin Accord, is an anthracycline antibiotic presented as an intravenous formulation for use in the treatment of acute myeloid leukemia in adult patients. It is manufactured to European Union standards and is indicated for induction and consolidation chemotherapy protocols.

GNH USA supplies Idarubicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable sourcing for oncology treatment programs.

Idarubicin Accord is an anthracycline chemotherapy agent used in the management of acute myeloid leukemia.

Acute Myeloid Leukemia (newly diagnosed): achieves remission by eradicating leukemic blasts during induction therapy. Acute Myeloid Leukemia (relapsed or refractory): provides disease control when other regimens have failed. Acute Myeloid Leukemia (consolidation): helps maintain remission by eliminating residual disease after induction.

Idarubicin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Fatigue and weakness - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Mucositis (inflammation of the mouth lining) - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity (heart failure, reduced ejection fraction) - Severe infections due to profound neutropenia - Hemorrhage from thrombocytopenia - Secondary malignancies (e.g., therapy‑related leukemia) - Hepatic toxicity (elevated transaminases) - Pulmonary toxicity (interstitial pneumonitis)

When using Idarubicin Accord, clinicians should observe several precautionary measures to minimize risk.

Cardiac monitoring: perform baseline and periodic echocardiograms to detect cardiotoxicity. Hematologic monitoring: conduct regular complete blood counts to manage myelosuppression. Renal function assessment: evaluate kidney function before and during therapy. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Use caution in elderly patients: adjust monitoring due to increased susceptibility. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Idarubicin can interact with other medicines, affecting efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other anthracyclines or trastuzumab: markedly increases risk of cardiotoxicity. - Co‑administration with high‑dose cyclophosphamide: amplifies bone‑marrow suppression. - Combination with live vaccines: may cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise idarubicin plasma levels. - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce drug exposure. - Anticoagulants (e.g., warfarin): increased bleeding risk from thrombocytopenia. - Nephrotoxic agents (e.g., cisplatin): heightened renal toxicity when combined.